YM BioSciences to acquire DELEX Therapeutics

15-Apr-2005

YM BioSciences Inc. announced it has entered into a binding agreement, subject to the fulfillment of certain preconditions, in respect of the purchase of DELEX Therapeutics Inc. (Mississauga, Canada), a private clinical stage biotechnology company developing inhalation delivered fentanyl products to treat cancer pain, pursuant to which DELEX will become a wholly-owned subsidiary of YM BioSciences.

DELEX is advancing AeroLEF(TM), a proprietary technology for the treatment of acute and breakthrough pain, conditions that are common in cancer patients and underserved by existing technology. AeroLEF(TM) is an inhalation delivery system that delivers both free and liposomal encapsulated fentanyl, an opioid drug widely prescribed to treat cancer pain. This product has completed a Phase IIa trial with positive results and further efficacy trials in acute and cancer pain are planned for initiation in 2005.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance